logo
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

CARMIEL, Israel, July 21, 2025 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the appointment of Gilad Mamlok to serve as the Company's new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. To ensure a seamless transition, Mr. Mamlok has joined the company and is working alongside Mr. Rubin. After his tenure as Chief Financial Officer ends, Mr. Rubin will continue to be available to the Company as necessary until October 2025.
'With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy, and I am delighted to welcome him to the Protalix team,' said Dror Bashan, Protalix's President and Chief Executive Officer. 'I also want to thank Mr. Rubin, both personally and on behalf of Protalix and its Board of Directors, for his unwavering dedication and leadership. Over the last six years, Eyal and I have worked in a close, collaborative manner in the management of the Company. He contributed significantly to Protalix's transformation, strengthening the Company's capital and financial status and preparing the Company for growth. We wish Eyal success in his future endeavors.'
Mr. Mamlok is a seasoned financial executive with three decades of experience in healthcare and technology companies. He has an extensive background in capital markets transactions, mergers and acquisitions, business development and investor relations as well as in corporate governance matters. Most recently, he served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space. Prior to his role at TytoCare, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.
About Protalix BioTherapeutics, Inc.Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs–related diseases; and others.
Forward-Looking StatementsTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms 'expect,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'plan,' 'should' and 'intend' and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.
Investor ContactMike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306mmoyer@lifesciadvisors.com
Logo – https://mma.prnewswire.com/media/999479/5422505/Protalix_Biotherapeutics_Logo.jpg
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EROAD and Geotab Expand Existing Partnership in Australia with NHVR-Compliant Heavy Vehicle Solutions
EROAD and Geotab Expand Existing Partnership in Australia with NHVR-Compliant Heavy Vehicle Solutions

Malaysian Reserve

time37 minutes ago

  • Malaysian Reserve

EROAD and Geotab Expand Existing Partnership in Australia with NHVR-Compliant Heavy Vehicle Solutions

The offering deepens the EROAD + Geotab collaboration and provides Australian fleets with a unified, single-vendor solution for heavy vehicle compliance. AUCKLAND, New Zealand, July 30, 2025 /PRNewswire/ — EROAD, a global leader in connected fleet management solutions, today announced a new development in its growing and successful partnership with global telematics leader Geotab, bringing a broader suite of heavy vehicle compliance solutions to Australian fleet operators. The partnership provides a wide range of heavy transport operators in Australia, from long-haul carriers to fleets focusing on last mile delivery, with a scalable and future-ready technology platform. Geotab's TCA certified application service provider status and heavy transport offering paired with EROAD's experience in heavy transport, compliance, fuel tax credit solutions, and video telematics, builds on the current partnership for light commercial vehicle solutions already available today. Through this expansion, Australian customers have a seamless way to manage vehicle telematics and regulatory compliance, with full support for National Heavy Vehicle Regulator (NHVR) requirements, including Road Infrastructure Management (RIM), Telematics Monitoring Application (TMA), and certified Electronic Work Diary (EWD) functionality in a single platform. 'This marks an exciting evolution of our partnership with Geotab,' said Mark Davidson, Chief Product Officer at EROAD. 'Australian fleet operators, especially those managing heavy vehicles, are under growing pressure to stay compliant, safe, and efficient. By delivering a comprehensive, NHVR-compliant solution, we're helping simplify operations and reduce the complexity of dealing with multiple providers as well as improving the user experience with a single software platform'. The technology connects users to a full suite of enterprise solutions – including EROAD's Clarity Dashcam with Edge AI and Fatigue Monitoring. As Australian fleets adopt these purpose-built tools, they'll gain real-time visibility across fleet compliance, maintenance, safety, fuel tax credit claims, fatigue, and more. 'EROAD brings significant heavy vehicle expertise to Geotab's heavy transport solution,' said Andrew Hintz, Associate Vice President, Heavy Transport at Geotab. 'Adding this capability to the Australian market strengthens our joint offering and helps customers operate more confidently under NHVR regulations. Together, we're providing a more compliant, safer, and connected fleet management solution with a focus on superior customer service and support.' EROAD's Australian heavy transport solution, in partnership with Geotab, will be available in August. Customers can contact EROAD or Geotab to register interest and book a solution overview. About EROAD EROAD (NZX/ASX: ERD) is a hardware-enabled SaaS company delivering safety, compliance, sustainability and efficiency solutions for complex fleets. Its connected platform is used by commercial and government operators across New Zealand, Australia and North America to manage vehicles, assets and drivers with greater visibility and control. EROAD supports demanding, highly regulated fleet operations, including those moving food, concrete and aggregates, enabling them to operate smarter, safer and more sustainably. EROAD's platform is built on a foundation of regulatory expertise, having delivered the world's first GPS-based road user charging system in New Zealand, where it remains the market leader today. About GeotabGeotab is a global leader in connected vehicle and asset solutions, helping fleets boost their efficiency and management. We use advanced data analytics and AI to transform fleet performance, safety, and sustainability, reducing costs and driving efficiency. Supported by top data scientists and engineers, we serve over 55,000 customers worldwide, processing 80 billion data points daily from more than 4.7 million vehicle subscriptions. Geotab is trusted by Fortune 500 companies, mid-sized fleets, and the biggest public sector fleets globally, including the US Federal Government. Committed to data security and privacy, we hold FIPS 140-3 and FedRAMP authorisations. Our open platform, network of excellent partners, and Marketplace deliver hundreds of ready-to-go third-party solutions for fleets. This year, we are celebrating 25 years of innovation. Find out more at and follow us on LinkedIn.

FuturHealth to Deliver Affordable, FDA-Approved GLP-1s Nationwide
FuturHealth to Deliver Affordable, FDA-Approved GLP-1s Nationwide

Malaysian Reserve

time2 hours ago

  • Malaysian Reserve

FuturHealth to Deliver Affordable, FDA-Approved GLP-1s Nationwide

As restrictions tighten on compounded semaglutide, FuturHealth now offers name-brand GLP-1s—like Wegovy®— through Novo's cash-pay program SAN DIEGO, July 30, 2025 /PRNewswire/ — FuturHealth, a leading provider of personalized weight-loss solutions, today announced it is giving its members seamless access to FDA-approved GLP-1 medications – including Wegovy® – at highly affordable, cash-pay prices, delivered directly to their doors. This service is enabled by the proven home delivery capabilities of Alto Pharmacy, a leader in technology-powered pharmacy experiences and part of Fuze Health. Patients prescribed GLP-1 medications by FuturHealth's network of licensed providers will receive free, next-day delivery from Alto Pharmacy. Additionally, now through July 31, FuturHealth members can access Novo Nordisk's limited-time, $299 first-month offer for Wegovy® by visiting FuturHealth and accessing the Wegovy cash-pay program. After the first month, eligible participants can continue to receive the medication for $499 a month. Participants may also choose to pay over time through FuturHealth's Buy Now, Pay Later program with Affirm. 'Our mission is to make people successful in their health journey by offering a program that ensures our members have the best access to medications, in addition to the tools to make them successful with these medications,' said Luke Mahoney, co-founder and CEO of FuturHealth. 'We are delighted to provide our patients with seamless, fast and convenient home delivery.' The announcement comes as compounded semaglutide faces mounting legal restrictions, making access to name-brand alternatives more important than ever. In addition to medication fulfillment, FuturHealth's program includes physician-led care, lab work, custom meal plans, and ongoing behavioral support tools, creating a 360-degree experience for lasting results. For more information about FuturHealth's innovative approach, and to take FuturHealth's quiz, visit For more information about FuturHealth's consumer direct pricing program, visit About FuturHealth:FuturHealth is your partner in weight loss, providing personalized guidance designed to work with your everyday life. Together with a team of doctors, dieticians, and weight-loss experts, we combine scientifically-proven medications with clinically-crafted, expertly-curated meals for quick, easy, effective, and affordable wins. Founded with a mission to create a holistic and personalized alternative to traditional, one-size-fits-all weight-loss solutions, we meet each person where they are on their unique journey, empowering them to confidently take control of their well-being at every step of the way. With a network of 350+ providers across 48 states, FuturHealth has transformed the lives of over 1.5 million patients and counting. In under a year, it has achieved an extraordinary 980% growth in active patients and facilitated over 6 billion online interactions.

Health Gorilla Joins CMS-Aligned Network as a Trusted Data Network Enabling AI-Ready Clinical Data Exchange
Health Gorilla Joins CMS-Aligned Network as a Trusted Data Network Enabling AI-Ready Clinical Data Exchange

Malaysian Reserve

time2 hours ago

  • Malaysian Reserve

Health Gorilla Joins CMS-Aligned Network as a Trusted Data Network Enabling AI-Ready Clinical Data Exchange

CORAL GABLES, Fla., July 30, 2025 /PRNewswire/ — Health Gorilla, a designated Qualified Health Information Network (QHIN) under the Trusted Exchange Framework and Common Agreement (TEFCA), today announced its participation as one of the inaugural data network early adopters in the CMS-Aligned Network. Recognized by the Centers for Medicare & Medicaid Services (CMS) as a trusted exchange partner, Health Gorilla brings a unique capability to the initiative: enabling secure, standards-based access to AI-ready structured clinical data at national scale. Unveiled at a White House convening of over 30 leading healthcare and technology organizations, the CMS-Aligned Network represents a foundational step toward a more connected, patient-centric health data ecosystem. Health Gorilla's Chief Operating Officer, Patrick Lane, attended the event on behalf of the company. 'The CMS-Aligned Network sets the stage for a new era of healthcare,' said Patrick Lane, President and Chief Operating Officer at Health Gorilla. 'As a TEFCA-designated QHIN, we not only support trusted exchange—we deliver deduplicated, normalized, and AI-ready data that patient-facing app developers, payers, and providers need to build tools that actually improve care. That's the difference we bring to this initiative.' Enabling Intelligent Interoperability Across the CMS Health Tech Ecosystem As one of the first operational QHINs and a CMS-recognized data network, Health Gorilla offers: AI-Ready Data at Scale – Health Gorilla transforms raw clinical records into structured, normalized, and deduplicated data—delivered through secure FHIR APIs to power advanced analytics, decision support, and intelligent applications. FHIR-Native, TEFCA-Compliant Exchange – Enabling real-time data sharing across payers, providers, public health agencies, and digital health platforms, all aligned with national policy and technical frameworks. Trusted Infrastructure for Ecosystem Builders – Supporting secure digital identity, provider directory resolution, and consented access to complete patient records—all foundational elements of CMS's long-term vision. By participating in the CMS-Aligned Network, Health Gorilla will also support CMS's ability to engage in trusted exchange by 2026, enabling data access for beneficiaries and providers through modern, secure digital channels. 'In today's landscape, it's not just about connecting data—it's about making it usable, trustworthy, and intelligent,' Lane added. 'We're proud to deliver the infrastructure and the data quality that the CMS Health Tech Ecosystem will rely on.' About Health Gorilla Health Gorilla, a designated QHIN under TEFCA, is a leading national interoperability platform delivering secure, real-time access to structured, AI-ready health data. Health Gorilla supports EHR vendors, value-based care organizations, and digital health innovators with data-driven workflows that enable more informed, connected, and efficient care. Media Contact:Grace VintonAmendola for Health Gorilla203-561-8935gvinton@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store